Compare GKOS & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | VSAT |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.6B |
| IPO Year | 2015 | 1996 |
| Metric | GKOS | VSAT |
|---|---|---|
| Price | $100.96 | $46.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $133.07 | $43.60 |
| AVG Volume (30 Days) | 577.7K | ★ 1.2M |
| Earning Date | 04-29-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.34 | $5.34 |
| Revenue Next Year | $27.46 | $3.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $7.36 |
| 52 Week High | $130.23 | $52.70 |
| Indicator | GKOS | VSAT |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 49.99 |
| Support Level | $94.92 | $41.76 |
| Resistance Level | $104.66 | $49.81 |
| Average True Range (ATR) | 4.02 | 3.19 |
| MACD | -0.71 | 0.15 |
| Stochastic Oscillator | 22.45 | 36.59 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.